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A b s t r a c t
Introduction: Socioeconomic determinants of prostate-specific antigen 
(PSA) testing and prevalence of undiagnosed prostate cancer (PCa) in the 
Polish population are poorly understood. The aim of this study was to iden-
tify factors associated with PSA testing in elderly Polish men, and estimate 
the size of the population at risk of PCa related to PSA non-testing.
Material and methods: We analyzed questionnaire-derived data concern-
ing PSA testing, obtained in 2567 elderly and 332 younger (age: 55–59) 
participants of the population-based PolSenior study. Additionally, PSA was 
measured in 2414 subjects.
Results: The PSA had previously been tested in 41.2% of elderly and in 24.8% 
of younger participants. Non-smoking status (OR = 2.06, p < 0.001), higher per-
sonal income (OR = 1.56, p < 0.001), better education (OR = 1.49, p = 0.001), 
previous white-collar work (OR = 1.37, p = 0.005), alcohol abstinence (OR = 
1.28, p = 0.02), married status (OR = 1.24, p = 0.04), dependence in Instru-
mental Activities of Daily Living (IADL) but not in Activities of Daily Living 
(ADL) (OR = 0.65, p < 0.001), and dependence in ADL (OR = 0.55, p < 0.001) 
were independent predictors of previous PSA testing in elderly participants. 
There were 31 elderly previously treated for PCa (calculated standardized 
prevalence: 935 per 100,000 elderly population). The PSA levels > 4 ng/ml 
were found in 12.8% of 65–74-year-old and 4.5% of 55–59-year-old previ-
ously non-tested participants. We calculated the standardized prevalence 
rate of undiagnosed PCa as approximately 1370 and 2352 cases per 100,000 
population aged 55–59 and 65–74 years, respectively.
Conclusions: In Poland, 58.8% of elderly men have never had PSA tested. 
These were less likely to be functionally independent, married, better edu-
cated, non-smokers or to have previous office employment or higher than 
average personal income. Our data suggest substantial underdiagnosis of 
prostate cancer among Polish men.
Key words: epidemiology, prostate cancer screening, prostate-specific 
antigen, screening.
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Introduction
Prostate cancer (PCa) is the most common can-
cer affecting men in the developed countries [1, 2]. 
In Poland, PCa accounted for 14.4% of all cancer 
cases among men in 2011, making it the second 
most common cancer in males. The lifetime risk for 
PCa in the United States is estimated at 15.9%, and 
the risk of death is 2.3% [1]. The expected survival 
in treated patients is at least 10 to 15 years [3]. 
The highest incidence of PCa has been report-
ed in Europe (111 cases per 100,000 men per 
year) and North America (101 cases per 100,000 
men per year) [1]. According to the report of the 
Polish National Cancer Center, morbidity from PCa 
(the standardized incidence rate) almost doubled 
from 18.3/100,000 in 1999 to 36.1/100,000 in 
2012, with the highest incidence among men aged 
70–74 years (2122/100,000 in 2012) [4]. By 2020 
the incidence of PCa among elderly Polish men is 
expected to increase by 30% and reach approxi-
mately 13,000 cases annually [5]. It is mostly due to 
screening measures (e.g. digital rectal examination 
(DRE) and prostate-specific antigen (PSA) testing) 
and more frequent prostate biopsies in patients 
with elevated PSA levels (> 4 ng/ml for Caucasians). 
Only one published study has analyzed PSA test-
ing in Poland. This was a  large population-based 
survey of 28 European countries (including Poland) 
conducted in 2006 (Eurobarometer 66.2 “Health in 
the European Union”). It found that only 22% of 
men aged 40 years and older had had a PSA test in 
the previous 12 months, with large regional vari-
ability (5–43%) [6]. Age, education level, marital 
status, smoking habit, and socio-economic status 
were associated with the likelihood of screening. 
The highest PSA testing uptake was among men 
aged 70 years or more. Unfortunately, the PSA test 
lacks sensitivity and specificity for early PCa [7]. 
Therefore, benefits of PSA screening in the very 
elderly are uncertain, and may not outweigh the 
harms, due to the risk related to unnecessary biop-
sies, overdetection, and overtreatment [8].
Low utilization of PSA and DRE testing recom-
mended by the Polish Association of Urology in 
line with European Association of Urology (EAU) 
in men aged 40–75 years [9] results in late diag-
nosis of symptomatic PCa (locally advanced and/
or metastatic disease) and palliative treatment. 
However, a  recently performed review of the 
available literature found strong evidence that for 
PSA-based screening the benefits may outweigh 
harms in men aged 55–69 years [10].
On the other hand, the increasing life expec-
tancy results in a growing population older than 
75 years with very good health, who are likely to 
live at least another 10 years. This group of men 
may benefit from routine PSA screening, accord-
ing to American guidelines [11]. 
The recently completed PolSenior study includ-
ed information on PSA testing in a  large repre-
sentative elderly Polish population. Data from the 
PolSenior study allow analysis of the rate of PSA 
testing in relation to a much wider range of deter-
minants than previous studies.
The aim of this study was to identify factors 
associated with PSA testing in elderly Polish men 
and estimate the size of the population at risk of 
PCa related to PSA non-testing.
Material and methods
We analyzed data obtained concerning 2,567 
men aged 65 years or more, and 332 men 55–59 
years old, participants of the PolSenior popula-
tion-based, multicenter, interdisciplinary study, 
conducted from 2007 to 2012. The study was 
designed to assess the health and socio-econom-
ic status of elderly individuals in Poland. It was 
based on a standardized questionnaire with ele-
ments of a  comprehensive geriatric assessment, 
blood pressure and anthropometric measure-
ments, and some blood and urine analyses [12]. 
The study protocol was approved by the Bioethics 
Commission (KNW-6501-38/I//08) and informed 
consent was obtained from each participant. 
The questionnaire contained items concerning 
the participant’s personal history of PCa treated 
with chemotherapy, radiotherapy, surgery, an-
tiandrogens, or gonadotropin-releasing hormone 
(GnRH) analogs, and PCa screening on the basis of 
PSA testing in the past. 
Additionally, serum PSA levels were determined 
in the 2,122 elderly (> 65 years, 82.7%) and 292 
younger (55–59 years, 88.0%) participants who 
agreed to venesection (Roche Diagnostics GmbH; 
Mannheim, Germany for Roche Elecsys 2010 an-
alyzer). 
Study questionnaire
Previous PSA testing was determined by closed 
multiple-choice question (Have you ever had your 
PSA blood level tested? Once/more than once/
never/don’t know or don’t remember), supple-
mented by nurses on the basis of medical records 
held by the participants. 
Prevalence of PCa was based on medical histo-
ry and treatment for PCa, including antiandrogen-
ic drugs and GnRH analogs. 
Data analysis
We included the following factors as potential 
determinants of PSA testing: nutritional status 
(based on body mass index (BMI), according to 
World Health Organization criteria), smoking sta-
tus, alcohol consumption, place of residence (and 
city size), level of education, marital status, type 
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of work in the past (office or manual worker), cur-
rent personal income (low (below average income 
in the Polish population in 2008), median, or high 
(2 times higher than average)), independence 
as assessed by the Katz Activities of Daily Living 
(ADL) scale (disabled < 5 points), and Instrumental 
Activities of Daily Living (IADL) as assessed by the 
Lawton scale (disabled < 24 points). 
Measured serum PSA levels were stratified 
into 3 groups: ≤ 4, > 4 but ≤ 10, and > 10 ng/ml. 
Using the positive predictive value for PSA levels 
for detection of PCa in biopsy (32% for PSA levels 
> 4.0 [13]) we calculated the estimated prevalence 
of undiagnosed PCa in the entire Polish elderly 
population.
Statistical analysis
All statistical analyses were performed using 
SAS software version 9.1.3 (SAS Institute Inc., 
Cary, NC). Distribution of qualitative variables 
was shown by their absolute and relative fre-
quencies. Distribution of quantitative variables 
was expressed as mean and standard deviation. 
Differences in the distribution of qualitative vari-
ables were analyzed using the c2 test, and p < 0.05 
was considered significant in univariate analyses. 
As the study sample had equal numbers in each 
age stratum, mean values in each stratum were 
weighted to allow for the actual age distribution 
in Poland. The standardized prevalence of PCa 
and undiagnosed PCa in the Polish elderly popu-
lation (aged 65–74 years) in 2009 was calculated 
from these weighted means. Multivariate analy-
sis of determinants of PSA testing was performed 
by logistic regression (Proc Logistic, SAS) with 
backward selection of explanatory variables. The 
dependent variable was PSA testing at any time 
in the past (yes/no) and the set of independent 
variables (complete model) including age, place of 
residence, education level, type of work, personal 
income, smoking habit, alcohol consumption, dis-
ability and nutritional status. All examined deter-
minants were qualitative variables (definition in 
Table I). The results of multivariate analysis were 
interpreted using logistic odds ratios (and their 
95% CIs), in addition to statistical significance of 
regression coefficients (criterion: p < 0.05).
Results
PSA testing in the past 
Two hundred eighty subjects (270 elderly, 10 
aged 55–59 years) who did not respond clearly to 
Table I. PSA testing according to age, socioeconomic factors, and other variables in elderly subjects in Poland. 
Results of univariate logistic regression analysis. OR values and 95% confidence intervals
Variable Level Univariate regression
OR
P-value Multiple backward
regression
OR  
P-value
Age [years] 70–74 vs. 65–69 1.33 (1.00–1.76) 0.2 – –
75–79 vs. 65–69 1.29 (0.96–1.73) –
80–84 vs. 65–69 1.30 (0.97–1.75) –
85–89 vs. 65–69 1.20 (0.90–1.61) –
≥ 90 vs. 65–69 1.04 (0.76–1.42) –
Residence City vs. rural 1.22 (0.90–1.64) 0.001 – –
Marital status Married vs. unmarried 1.19 (1.01–1.41) 0.03 1.24 (1.01–1.53) 0.04
Education level Secondary/higher vs. 
other
2.27 (1.85–2.71) < 0.001 1.49 (1.16–1.91) 0.001
Type of work Office worker vs. 
manual worker
2.42 (2.00–2.93) < 0.001 1.37 (1.09–1.71) 0.005
Personal income High/medium vs. low 2.03 (1.64–2.51) < 0.001 1.56 (1.26–1.93) < 0.001
Smoking No vs. yes 2.25 (1.73–2.93) < 0.001 2.06 (1.54–2.78) < 0.001
Alcohol 
consumption
No/seldom vs.
frequently 
1.35 (1.11–1.64) 0.002 1.28 (1.03–1.60) 0.02
Disability ADL disability* vs. no 0.61 (0.47–0.80) < 0.001 0.58 (0.39–0.85) < 0.001
IADL disability vs. no 0.69 (0.50–0.79) < 0.001 0.66 (0.50–0.86) < 0.001
Nutritional status Obese/overweight vs. 
normal weight
1.17 (0.97–1.32) 0.1 – –
*Excluding disabled in ADL.
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the questions were excluded from the analysis. Se-
rum PSA had been previously tested in 947 of 2297 
elderly (41.2%) and only 80 of 322 participants 
aged 55–59 years (24.8%), p < 0.001 (Figure 1). 
In 539 (23.5%) elderly and 31 (9.6%) younger sub-
jects, PSA had been tested more than once.
Therefore, 72.2% of younger men and 62.4% 
(weighted mean) of elderly ones aged 65–74 years 
had never been tested for PSA.
Prostate-specific antigen was tested most fre-
quently in the 70–74 years age group (Figure 1). 
Factors associated with increased probability 
of previous PSA testing were residence in a  city, 
being married, better educated, previous office 
employment, higher personal income, and in-
dependent in IADL (Tables I and II). Among IADL 
items, mode of transportation was strongly asso-
ciated with probability of PSA testing (OR = 0.57 
(0.45–0.71) for those who do not travel at all). In 
addition, PSA was more likely to be tested in over-
weight or obese men, nonsmokers, and those who 
consumed alcohol more than 3 times a week (Ta-
ble II). The results of a backward model of multiple 
logistic regression analysis showed that the sta-
tistically significant determinants of PSA testing 
were current non-smoking status, disability, edu-
cational level, type of work in the past, personal 
income, marital status and pattern of alcohol con-
sumption (Table I).
Prostate cancer (PCa)
Among the 2,567 elderly participants, 31 (1.3%) 
were treated for PCa (calculated standardized 
prevalence rate in the elderly Polish population, 
935 cases per 100,000 men). The percentage 
of subjects with PCa did not differ significantly 
across age groups. Men who consumed alcohol 
frequently were treated less often (Table I).
Among 332 younger participants (aged 55–59 
years), 2 (0.6%) were treated for PCa.
PSA levels
Prostate-specific antigen levels were elevated 
(> 4 ng/ml) in 433 of the 2,122 elderly men tested 
(20.4%), including 298 (14%) with PSA 4–10 ng/
ml and 135 (6.4%) with PSA > 10 ng/ml. Among 
292 younger participants tested, elevated PSA 
was found in 13 (4.5%), including 10 (3.4%) with 
PSA 4–10 ng/ml and 3 (1.0%) with PSA > 10 ng/ml 
(Figure 2). 
In the 415 elderly subjects, aged up to 75 
years, who had not previously been treated for 
PCa or been tested for PSA, elevated serum PSA 
levels were observed in 53 (12.8% of non-test-
ed and 7.3% of the corresponding elderly study 
group). Of those 53 with elevated PSA, 41 had 
PSA 4–10 ng/ml and 12 had PSA > 10 ng/ml. In 
the 242 younger subjects who had not previously 
been treated for PCa or tested for PSA, elevated 
serum PSA levels were observed in 13 (5.2% of 
non-tested and 4.5% of the younger study group) 
– Figure 3.
Published data suggest that there is a  32% 
prevalence of PCa in patients who have not pre-
viously been treated for PCa and who have PSA > 
4 ng/ml [13]. Assuming that this prevalence ap-
plied to our study population, we calculated that 
4 of 13 aged 55–59 years, 8 of 24 aged 65–69 
years, and 9 of 29 aged 70–74 years probably had 
undiagnosed PCa. Based on this, we calculated 
the prevalence of undiagnosed PCa in the popula-
tion aged 55–59, 65–69 and 70–74 years as 1370, 
2432 and 2244 cases per 100,000 population of 
men, while the standardized prevalence rate for 
elderly (aged 65–74 years) Polish men is 2352 cas-
es per 100,000 population.
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Figure 1. Prevalence of previous testing for PSA in elderly (n = 2567) and younger (n = 332) men in the PolSenior 
study
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Table II. Previous PSA testing and prevalence of prostate cancer according to age, socioeconomic factors, and other 
variables in elderly subjects in Poland
Variable Level Prior PSA testing 
(%)
P-value Prostate cancer 
(%)
P-value
Age [years] 65–69 (n = 375) 34.9 0.03 0.5 0.3
70–74 (n = 481) 41.1 0.6
75–79 (n = 442) 39.5 1.1
80–84 (n = 420) 38.1 1.9
85–89 (n = 471) 35.2 1.7
≥ 90 (n = 378) 30.9 1.3
Residence Big city (n = 531) 45.2 < 0.001 1.9 0.2
City (n = 1016) 38.7 1.1
Rural (n = 991) 30.1 1.0
Marital 
status
Never married /divorced (n = 99) 32.3 0.02 1.0 0.9
Widowed (n = 650) 33.0 1.2
Married (n = 1730) 38.6 1.1
Education 
level 
No education (n = 36) 11.1 < 0.001 0 0.1
Primary incomplete (n = 236) 25.8 0.4
Primary (n = 971) 30.0 0.9
Vocational (n = 435) 36.6 1.4
Secondary (n = 535) 45.2 1.5
Higher (n = 270) 58.8 1.5
Type of work Office worker (n = 641) 52.5 < 0.001 1.8 0.09
Manual worker (n = 1562) 31.2 0.8
Farmer (n = 253) 34.7 0.8
Personal 
income 
Very low and low (n = 580) 27.0 < 0.001 0.5 0.4
Medium (n = 1238) 38.4 1.3
Higher (n = 335) 53.1 1.2
Smoking No (n = 2221) 38.9 < 0.001 1.3 0.7
Yes (n = 346) 23.9 0.9
Alcohol 
consumption
No (n = 605) 34.8 0.009 1.6 0.05
Seldom (n = 1285) 39.6 1.3
Frequently (n = 634) 33.1 0.5
IADL 
disability
No (n = 1794) 40.7 < 0.001 1.3 0.6
Yes (n = 708) 27.4 0.9
ADL 
disability
No (n = 2266) 38.1 < 0.001 1.2 0.9
Yes (n = 296) 27.7 1.0
Body mass 
index
Underweight (n = 39) 20.0 0.01 0 0.1
Normal weight (n = 683) 34.3 1.6
Overweight (n = 1081) 39.0 1.0
Obese (n = 619) 39.3 1.3
ADL – activities of daily living, IADL – instrumental activities of daily living.
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Discussion
Our findings provide pertinent information re-
garding the frequency of PSA testing as well as 
prevalence of diagnosed and undiagnosed PCa in 
elderly Polish men. We were able to link these fre-
quencies to socio-economic variables. 
In the PolSenior study, 41.2% of elderly and 
24.8% of men aged 55–59 years had previously 
been tested for PSA. The utilization of PSA testing 
in the elderly Polish population has not previously 
been described. The only available data are from 
the Eurobarometer 66.2 “Health in the European 
Union” study, reporting PSA testing during the 
previous 12 months in 28 European countries, in-
cluding Poland, in men aged 40 years or more [6]. 
The average proportion of the elderly population 
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Figure 2. Percentage of participants with elevated PSA levels in the PolSenior study (n = 2414)
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Figure 3. Percentage of participants with elevated PSA levels among those not treated for PCa and reporting no 
previous PSA tests (n = 1540) in the PolSenior study
having had a PSA test was 22% for all countries, 
almost twice the proportion in Poland (12%). The 
difference between the Eurobarometer 66.2 and 
the PolSenior study is related to their methodolo-
gy. In the first one, only PSA tests performed within 
the previous 12 months were scored, while in the 
second there was no time limit to count the test.
The results of our study show that PSA screen-
ing in Poland is performed in one fourth (24.8%) 
of men aged 55–59. The use of the test increases 
with age up to 41.1% of those aged 70–74 years. 
The probability of having been tested for PSA is 
not related to the place of residence, but is strong-
ly determined by socio-economic factors: better 
education, prior office work, higher than average 
personal income, as well as marital status, inde-
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pendence both in IADL and ADL, and self-care for 
own health (nonsmokers, nondrinkers). These 
sociodemographic data are partially in line with 
an Australian study reporting that current smok-
ers were 15% to 20% less likely than those who 
have never smoked to undergo PSA testing [14]. 
Similarly, our results partly agree with the results 
of Eurobarometer 66.2 “Health in the European 
Union” reporting PSA testing during the previous 
12 months in 15% of smokers and 25% of non-
smokers [6]. However, the results obtained in our 
study show a much stronger effect of marital sta-
tus and education than reported in the European 
study [6]. Our results demonstrate lower rates of 
PSA testing by disabled elderly men. The effect 
of impaired IADL without impairment in ADL was 
associated with lower rates of PSA testing. This 
association has not been reported previously.
The PolSenior study shows that 62.4% (weight-
ed mean) of elderly men aged 65–74 years and 
72.2% of younger ones had never been tested for 
PSA. In the oldest groups, the low rate of screen-
ing can be explained by the restricted availability 
of PSA testing more than 2 decades ago. In young-
er men, the explanation is more likely to be due 
to poor self-care and low utilization of preventive 
medical services. 
It has already been shown that serum PSA con-
centrations in excess of the median for that age 
group better predict PCa than family history or 
race [15]. Thus, annual PSA tests are recommend-
ed in men aged 40–75 years [16]. However, the 
predictive value of elevated total PSA for cancer 
decreases with age, because of the increasing 
prevalence of benign prostate hyperplasia (BPH) 
in elderly men [17, 18]. 
Additionally, it should be stressed that the ben-
efits of early detection of PCa decrease with age 
because of the long natural history of PCa [19]. 
Thus routine PSA screening in men older than 75 
years does not appear to be beneficial. American 
guidelines recommend this procedure only for 
men in very good health with a family history of 
longevity, who are therefore likely to live at least 
another 10 years [11]. Even in these patients, PCa 
management should generally be limited to ob-
servation, with treatment offered only in aggres-
sive cases.
Rapid dissemination of PSA screening and eas-
ier access to transrectal ultrasound and prostate 
biopsy allows for early diagnosis of PCa and im-
plementation of radical therapy. The PCa diagno-
ses have increased substantially in Poland since 
the early 1990s. More than 70% of PCa cases and 
almost 90% of deaths due to PCa occur in men 
older than 65 years. However, mortality from PCa 
has not risen since the mid 1990s, due to earlier 
and more effective treatment [20]. The majority 
of PCas, including curable cases, are diagnosed in 
men with PSA levels less than 10.0 ng/ml, in the 
so-called “gray zone” [13, 21]. Our study demon-
strated that approximately 7% of Polish elder-
ly aged 65–74 years with PSA levels > 4.0 ng/dl 
had not previously been tested, and according 
to guidelines most of them (having considered 
the doubtful advantage in those with significant 
co-morbidity and poor health) should be referred 
to urologists for further assessment. This includes 
one fifth of subjects with PSA levels over 10.0 ng/
dl, expected to have about 50% risk of PCa. 
Our findings complement data provided by the 
National Cancer Center on the incidence and mor-
tality of PCa in Poland [4, 20] by adding an estima-
tion of PCa prevalence in the elderly. As was es-
timated in our study, the standardized prevalence 
rate of diagnosed (and treated) PCa in elderly men 
was 935 per 100,000 population. As could be ex-
pected, this value is much higher than the stan-
dardized incidence rate for this age group reported 
by the National Cancer Center in 2009 (322.2 per 
100,000 population) [4]. However, the small num-
ber of respondents with a  history of PCa in this 
study (n = 31) precludes a more detailed epidemi-
ological analysis, including nutritional status [22]. 
Our data show that further increases in the in-
cidence as well as in the prevalence of diagnosed 
PCa in the future can be expected. Presented 
results of PSA tests revealed a large group of re-
spondents who probably had undiagnosed PCa. 
Elevated PSA level (> 4 ng/ml) was found in 4.5% 
of younger and 7.3% of elderly (aged 65–74 years) 
participants of the PolSenior study who had not 
previously had a PSA test. Assuming the 32% risk 
of PCa in these individuals [13], we estimated the 
prevalence of undiagnosed PCa as 1370 cases per 
100,000 population of 55–59-year-old, and 2352 
cases per 100,000 population of 65–74-year-old 
elderly Polish men.
Our calculations, even assuming their overes-
timation, suggest that the prevalence of undiag-
nosed PCa in the youngest population of Polish 
elderly is higher than that of diagnosed elderly 
patients (935 vs. 2352 cases per 100,000 popu-
lation).
Our study has certain limitations related to the 
methodology of large population-based surveys 
assessing multidimensional aspects of health in 
the elderly and the self-reported nature of many 
data. The interview did not include questions 
about whether PSA tests were initiated by a doc-
tor or the subject himself, or the time of PSA 
testing. Additionally, the estimation of underdiag-
nosed PCa is based on data from a different eth-
nic population. However, there is a  lack of other 
studies showing the risk of PCa in elderly men in 
relation to PSA.
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It should be stressed that PSA and DRE remain 
the best documented screening tools. Genetic 
methods for identification of the population at 
risk are still beyond the horizon [23], even if her-
itable factors account for more than fifty percent 
of PCa [24].
In conclusion, in Poland, only 41.2% of older men 
have ever had a PSA test. Characteristics of those 
more likely to be tested for PSA include function-
al independence, being married, better educated, 
previous office employment, higher than average 
personal income and a healthy lifestyle (nonsmok-
er). Our data suggest substantial underdiagnosis 
of prostate cancer among Polish men.
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